TP53 and cancer: In another patient, GS clarified an inconclusive CMA result and confirmed the presence of a pathogenic partial gene deletion involving TP53. In addition, among the 7 patients with duplications involving cancer predisposition genes, GS revealed that 6 were tandem duplications, a crucial piece of information that could not be determined through other clinical assays, eg, MLPA or panel testing.